JY BioMedical Partners with Taipei Medical University to Advance Gamma Delta T Cell Therapy for Glioblastoma
- 博翔(Benjamin) 張
- Dec 1, 2024
- 2 min read
JY BioMedical is thrilled to announce a groundbreaking collaboration with Taipei Medical University to explore the potential of Gamma Delta (γδ) T cell therapy in treating glioblastoma (GBM), the most aggressive and lethal form of brain cancer. This industry-academia partnership marks a significant step forward in the development of innovative immunotherapies to address the unmet clinical needs of GBM patients.
The joint research project, titled "Evaluating the Potential of Gamma-Delta (γδ) T Cell Therapy in Treating Glioblastoma," aims to harness the unique properties of γδ T cells, which bridge innate and adaptive immunity. These cells demonstrate powerful cytotoxic effects against tumor cells, including glioblastoma, and their ability to overcome the immunosuppressive tumor microenvironment makes them a promising candidate for targeting resistant glioma stem cells that drive GBM recurrence.
Key Highlights of the Collaboration:
Comprehensive Research Approach: The study will evaluate the cytotoxic potential of γδ T cells in vitro and their efficacy in reducing tumor growth in an orthotopic GBM mouse model.
Advanced Methodologies: Cutting-edge techniques such as luciferase assays, caspase activation, and immunofluorescence imaging will be used to analyze tumor suppression and γδ T cell persistence.
Intracranial Injection Studies: This research will include testing γδ T cells' efficacy through direct intracranial injection into mouse models, assessing tumor growth and survival rates.
Dr. Tsung-Yi Hsu, Professor of Neuromedicine at Taipei Medical University and Principal Investigator of the project, expressed enthusiasm for the collaboration: “This partnership exemplifies the fusion of academic innovation and industry expertise. Together, we aim to push the boundaries of glioblastoma treatment by leveraging γδ T cells' unique capabilities.”
Dr. Benjamin Zhang, Chief Medical Officer of JY BioMedical, added: “As a company committed to advancing immunotherapy, we are excited to work with Taipei Medical University. This collaboration reflects our shared vision of translating scientific breakthroughs into life-saving treatments.”
About JY BioMedical
JY BioMedical is a biotechnology leader dedicated to developing transformative cell and gene therapies. The company focuses on leveraging cutting-edge science to create impactful solutions for cancer and immune-related diseases.
About Taipei Medical University
Taipei Medical University is a top-tier academic institution renowned for its innovative research and contributions to medical science. Its Neuromedicine Program is at the forefront of exploring novel therapeutic avenues for challenging diseases like glioblastoma.
For further information, please contact: service@jy-biomed.com
Comments